BURNABY, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon’s Chief Executive Officer, will participate in the following virtual investor conferences:
The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon’s website at www.xenon-pharma.com. When available, webcasts will be posted for replay following the event for 30 days.
About Xenon Pharmaceuticals Inc.
We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
LG NOVA Pushes Forward the Future of Collaboration and Innovation Across Healthtech, AI and Cleantech…
IRVINE, Calif., Jan. 03, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”)…
ZUG, Switzerland, Jan. 04, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes…
Greenville, South Carolina , Jan. 03, 2025 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the…
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade…
TORONTO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB:…